Profile data is unavailable for this security.
About the company
Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.
- Revenue in SEK (TTM)0.00
- Net income in SEK-15.01m
- Incorporated2011
- Employees2.00
- LocationModus Therapeutics Holding ABOlof Palmes gata 29 IVSTOCKHOLM 111 22SwedenSWE
- Websitehttps://www.modustx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTANA AB | 5.14m | -12.18m | 35.31m | 10.00 | -- | 2.18 | -- | 6.87 | -0.0361 | -0.0361 | 0.0148 | 0.0376 | 0.1715 | -0.4127 | 1.97 | 514,073.00 | -40.63 | -37.18 | -62.57 | -46.66 | 127.26 | 175.97 | -236.92 | -254.69 | 0.4858 | -4.43 | 0.158 | -- | -32.89 | 6.61 | 5.80 | -- | 8.21 | -- |
| Peptonic Medical AB | 39.05m | -45.25m | 35.68m | 37.00 | -- | 0.1917 | -- | 0.9138 | -0.025 | -0.025 | 0.0222 | 0.0323 | 0.4185 | 1.42 | 5.49 | 1,055,432.00 | -48.49 | -46.02 | -61.53 | -60.85 | 44.34 | 54.26 | -115.88 | -139.38 | 0.5002 | -140.41 | 0.2084 | -- | -14.93 | 149.65 | -15.55 | -- | 27.15 | -- |
| Fluicell AB | 1.30m | -27.16m | 37.36m | 11.00 | -- | 1.73 | -- | 28.81 | -0.1493 | -0.1493 | 0.0055 | 0.045 | 0.0525 | 0.5265 | 1.98 | 76,294.12 | -109.94 | -87.55 | -141.87 | -126.02 | -17.66 | 72.97 | -2,094.37 | -650.23 | 3.83 | -695.51 | 0.00 | -- | 2.68 | 22.18 | -22.90 | -- | -- | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 1.20m | -16.75m | 37.57m | 10.00 | -- | 10.10 | -- | 31.30 | -0.18 | -0.18 | 0.0125 | 0.0351 | 0.0949 | -- | 21.10 | 120,004.00 | -132.48 | -80.90 | -176.94 | -106.45 | -344.65 | -1,073.66 | -1,395.47 | -1,360.03 | 1.12 | -1.36 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Respiratorius AB (publ) | 1.35m | -7.30m | 37.63m | -- | -- | 0.9465 | -- | 27.94 | -0.0229 | -0.0229 | 0.0042 | 0.078 | 0.0461 | -- | -- | -- | -24.98 | -- | -26.52 | -- | 63.66 | -- | -542.36 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -9.55 | -- |
| Orphazyme A/S | 0.00 | -17.38m | 47.69m | 1.00 | -- | 1.95 | -- | -- | -325.75 | -325.75 | 0.00 | 455.65 | 0.00 | -- | -- | 0.00 | -42.26 | -76.08 | -50.77 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Combigene AB | 1.91m | -36.52m | 49.90m | 10.00 | -- | 0.5269 | -- | 26.07 | -1.84 | -1.84 | 0.0967 | 4.78 | 0.0161 | -- | 3.71 | 239,265.00 | -30.66 | -13.00 | -32.33 | -14.58 | -- | -- | -1,908.16 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Nidhogg Resources Holding AB (publ) | 32.00k | -4.21m | 54.09m | 3.00 | -- | 59.38 | -- | 1,690.42 | -0.0021 | -0.0021 | 0.00005 | 0.0005 | 0.0087 | -- | 0.0128 | 10,666.67 | -114.92 | -70.56 | -204.32 | -82.81 | -25,093.75 | -- | -13,156.25 | -- | -- | -- | -- | -- | -- | -- | 77.06 | -- | -- | -- |
| ViroGates A/S | 8.08m | -20.00m | 56.94m | 10.00 | -- | 4.01 | -- | 7.05 | -5.78 | -5.78 | 1.18 | 1.45 | 0.3331 | 0.3869 | 6.80 | 530,700.00 | -82.42 | -46.58 | -89.49 | -52.09 | 69.49 | 77.91 | -247.47 | -238.01 | 8.60 | -19.26 | 0.3626 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -15.01m | 59.84m | 2.00 | -- | 6.08 | -- | -- | -0.5898 | -0.5898 | 0.00 | 0.2738 | 0.00 | -- | -- | 0.00 | -165.57 | -141.06 | -- | -278.44 | -- | -- | -- | -- | -- | -18.39 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
| Ultimovacs ASA | 0.00 | -174.02m | 61.19m | 23.00 | -- | 0.2899 | -- | -- | -5.21 | -5.21 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -51.97 | -28.80 | -57.15 | -31.12 | -- | -- | -- | -- | -- | -114.19 | 0.0137 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Abera Bioscience AB | 0.00 | -7.63m | 62.48m | 6.00 | -- | 7.10 | -- | -- | -0.5213 | -0.5213 | 0.00 | 0.5733 | 0.00 | -- | -- | 0.00 | -73.37 | -79.42 | -98.59 | -96.10 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.74 | -- | -- | -- |
| PCI Biotech Holding ASA | 5.82m | -15.53m | 64.79m | 7.00 | -- | 2.09 | -- | 11.13 | -0.4287 | -0.4287 | 0.1607 | 0.8548 | 0.1334 | -- | 0.9365 | 857,000.00 | -35.59 | -36.44 | -40.42 | -40.14 | -- | -- | -266.74 | -1,055.43 | -- | -- | 0.0147 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Chosa Oncology AB | 5.00k | -8.58m | 76.62m | -- | -- | 3.54 | -- | 15,323.94 | -0.1745 | -0.1745 | 0.00009 | 0.3054 | 0.0002 | -- | 0.0009 | -- | -28.72 | -51.96 | -31.51 | -61.92 | -- | -- | -171,540.00 | -708.47 | -- | -28.22 | 0.00 | -- | -98.21 | -- | 28.33 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.81m | -35.86m | 80.78m | 12.00 | -- | 1.62 | -- | 44.61 | -0.2614 | -0.2614 | 0.0106 | 0.1436 | 0.0386 | -- | 2.43 | 139,307.70 | -76.46 | -20.19 | -86.74 | -20.97 | -97.96 | -- | -1,980.40 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Sprint Bioscience AB | 85.01m | 14.72m | 81.69m | 36.00 | 5.55 | 4.37 | 5.28 | 0.9609 | 0.2108 | 0.2108 | 1.22 | 0.2677 | 2.38 | -- | 13.18 | 3,036,214.00 | 41.28 | -71.22 | 128.58 | -113.71 | 76.51 | 62.75 | 17.31 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
Data as of Sep 20 2024. Currency figures normalised to Modus Therapeutics Holding AB's reporting currency: Swedish Krona SEK
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Aug 2024 | 3.39k | 0.01% |
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
